Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling-Reference-Cited by-同舟云学术

Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling

Published:2019-12-11 Issue:1 Volume:60 Page:349-359
ISSN:1549-9596
Container-title:Journal of Chemical Information and Modeling
language:en
Short-container-title:J. Chem. Inf. Model.

Author:

Hariono Maywan¹^ORCID,Nuwarda Rina F.²,Yusuf Muhammad³^ORCID,Rollando Rollando⁴,Jenie Riris I.⁵,Al-Najjar Belal⁶,Julianus Jeffry¹,Putra Kevin C.¹,Nugroho Ervan S.¹,Wisnumurti Yohanes K.¹,Dewa Sangga P.¹,Jati Benedictus W.¹,Tiara Reynaldo¹,Ramadani Ratna D.⁵,Qodria Lailatul⁵,Wahab Habibah A.⁷^ORCID

Affiliation:

1. Faculty of Pharmacy, Sanata Dharma University, Depok, Sleman 55282, Yogyakarta, Indonesia

2. Faculty of Pharmacy, Padjadjaran University, Jatinangor, Sumedang 45363, West Java, Indonesia

3. Chemistry Department, Faculty of Mathematics and Natural Sciences, Padjadjaran University, Jatinangor, Sumedang 45363, West Java, Indonesia

4. Pharmacy Program, Faculty of Science and Technology, Ma Chung University, Malang 65151, Indonesia

5. Cancer Chemoprevention Research Center, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara 55281, Yogyakarta, Indonesia

6. Faculty of Pharmacy and Medical Sciences, AlAhliyya Amman University, Amman 19328, Jordan

7. Pharmaceutical Technology Department, School of Pharmaceutical Sciences and USM-RIKEN Centre for Ageing Science (URICAS), Universiti Sains Malaysia, 11800 Minden, Pulau Pinang, Malaysia

Funder

Universiti Sains Malaysia

Indonesia Toray Science Foundation

Publisher

American Chemical Society (ACS)

Subject

Library and Information Sciences,Computer Science Applications,General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jcim.9b00630

Reference54 articles.

1. Cancer prevention from the perspective of global cancer burden patterns

2. Mechanisms and insights into drug resistance in cancer